Phase II study of simultaneous infusion of levozolinate for injection and 5-FU as first-line treatment for advanced colorectal cancer
The subjects voluntarily joined this study and signed the informed consent form.
Age: 18 to 75 years old, gender not limited;
ECOG PS score: 0-2 points
Patients with unresectable or metastatic colorectal cancer confirmed by histology or cytology, where the primary tumor location and the status of RAS and BRAF are known;
Those who have been confirmed to be allergic to the test drug and/or its excipients;
Those with contraindications to chemotherapy;
Colorectal cancer patients with MSI-H or dMMR;
Pregnant or lactating women;